238 related articles for article (PubMed ID: 20593935)
1. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
Ezat WP; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
Ezat SW; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
11. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals.
Han KT; Kim SJ; Lee SY; Park EC
Asian Pac J Cancer Prev; 2014; 15(19):8503-8. PubMed ID: 25339055
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
14. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.
Konno R; Sasagawa T; Fukuda T; Van Kriekinge G; Demarteau N
Int J Gynecol Cancer; 2010 Apr; 20(3):385-92. PubMed ID: 20375802
[TBL] [Abstract][Full Text] [Related]
18. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
19. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
